# NCT07545122 (NCT07545122)

> A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

No report yet. It can be ordered.

- Drugs tested: CT-202
- Indication: recurring triple negative breast, colorectal and urothelial cancers

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07545122
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Context Therapeutics Inc.
- Conditions: Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Urothelial Cancer
- Interventions: CT-202
- Enrollment: 162
- Primary outcome: Phase 1a: Incidence of Dose Limiting Toxicities (DLTs)
- Primary outcome: Phase 1b: Overall response rate (ORR)

## Indexed commentary on NCT07545122 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct07545122
